LeMaitre Vascular (NASDAQ:LMAT) CEO Sells $3,030,385.89 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $98.17 on Thursday. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average price is $109.69 and its 200-day moving average price is $94.82. LeMaitre Vascular, Inc. has a 52 week low of $78.35 and a 52 week high of $118.01. The stock has a market cap of $2.24 billion, a P/E ratio of 36.23, a P/E/G ratio of 2.70 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million for the quarter, compared to analysts’ expectations of $66.67 million. During the same period in the previous year, the firm posted $0.48 EPS. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is presently 36.90%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sound Income Strategies LLC boosted its holdings in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 183 shares during the last quarter. Cornerstone Planning Group LLC boosted its holdings in shares of LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 283 shares during the last quarter. Catalyst Capital Advisors LLC bought a new position in shares of LeMaitre Vascular during the 1st quarter valued at about $32,000. MAI Capital Management bought a new position in shares of LeMaitre Vascular during the 3rd quarter valued at about $38,000. Finally, First Horizon Corp bought a new position in shares of LeMaitre Vascular during the 3rd quarter valued at about $39,000. Institutional investors own 84.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on LMAT shares. Barrington Research boosted their price objective on shares of LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Roth Mkm reissued a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Citizens Jmp upped their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Finally, Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.